Breast Cancer, Sexuality and Black Cohosh
The purpose of this study is to evaluate the Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen or aromatase inhibitor through questionnaires.
Sexuality
BEHAVIORAL: WHOQOL questionnaire|BEHAVIORAL: FSFI questionnaire|BEHAVIORAL: kupperman scale|DRUG: Cimicifuga racemosa|DRUG: tamoxifen|DRUG: exemestane
Hot flashes (score of hot flashes), Determine the score of hot flashes, 6 months
Sexual function (score of sexual function questionnaire (FSFI), Determine the score of sexual function questionnaire (FSFI), 3 months|Sexual function (score of sexual function questionnaire (FSFI), Determine the score of sexual function questionnaire (FSFI), 6 months
Quality of life (questionnaire scores of quality of life (WHOQOL), Determine the questionnaire scores of quality of life (WHOQOL), 3 months|Quality of life (questionnaire scores of quality of life (WHOQOL), Determine the questionnaire scores of quality of life (WHOQOL), 6 months
For the study will be recruited 60 women treated with breast cancer, using tamoxifen or aromatase inhibitor, are in menopause, hot flashes and has with or without sexual life. They will answer the questionnaires: Kupperman, World Health Organization Quality of Life (WHOQOL) and those sexually active will have Female Sexual Function Index (FSFI). The control group will have 30 patients using tamoxifen alone or inhibitor. The other group will have 30 patients receiving tamoxifen or inhibitor and will start with 2 tablets per day of dry extract of Cimicifuga racemosa. They will be followed for 6 months and answer questionnaires at the first visit, 3-month and 6-month follow-up.